Characteristics of chronic myelogenous leukemia (CML) patients rndergoing non-ablative stem cell transplantation (Flag-Ida) or reduced intensity conditioning (fludarabine/melphalan) at M.D. Anderson Cancer Center.
| Parameter . | Flag-Ida . | Fludarabine/Melphalan . |
|---|---|---|
| Number | 10 | 33 |
| Median age, (range) | 57 (42-72) | 52 (24-70) |
| Median time to BMT in months, (range) | 29 (13-11) | 29 (3-220) |
| Stage at BMT | ||
| first chronic | 5 | 8 |
| phase transformed | 5 | 25 |
| Donor type | ||
| sibling | 8 | 15 |
| unrelated | 2 | 18 |
| Comorbid conditions | ||
| age > 55 year | 6 | 13 |
| extensive prior therapy | 0 | 23 |
| infection/organ function/PS = 2 | 3 | 6 |
| none | 1 | 6 |
| Parameter . | Flag-Ida . | Fludarabine/Melphalan . |
|---|---|---|
| Number | 10 | 33 |
| Median age, (range) | 57 (42-72) | 52 (24-70) |
| Median time to BMT in months, (range) | 29 (13-11) | 29 (3-220) |
| Stage at BMT | ||
| first chronic | 5 | 8 |
| phase transformed | 5 | 25 |
| Donor type | ||
| sibling | 8 | 15 |
| unrelated | 2 | 18 |
| Comorbid conditions | ||
| age > 55 year | 6 | 13 |
| extensive prior therapy | 0 | 23 |
| infection/organ function/PS = 2 | 3 | 6 |
| none | 1 | 6 |